Margenza FDA Approval History
FDA Approved: Yes (First approved December 16, 2020)
Brand name: Margenza
Generic name: margetuximab-cmkb
Dosage form: Injection
Company: MacroGenics, Inc.
Treatment for: Breast Cancer
Margenza (margetuximab-cmkb) is a HER2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2- positive breast cancer.
Development Timeline for Margenza
|Dec 16, 2020||ApprovalFDA Approves Margenza (margetuximab-cmkb) for Patients with Pretreated Metastatic HER2-Positive Breast Cancer|
|Dec 19, 2019||MacroGenics Announces Submission of Margetuximab Biologics License Application to U.S. FDA|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.